| 研究成果： |
发表SCI论文：
[1]Liang M, Zhao TG, Ma LF, Guo YJ*. CHK1 inhibition sensitises pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. Oncology Reports 39(3):1322-1330, 2018.
[2] Zhou JK, Zhao TG, Ma LF, Liang M, Guo YJ*, Zhao LM*. Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling. Oncotarget 8(61):103167-103181, 2017.
[3] Zou LY, Zhu JX, Dong Y, Han WW*, Guo YJ*, Zhou H*. Models for the binding channel of wild type and mutant transthyretin with glabridin. RSC Adv. 6: 96816-96823, 2016.
[4] Wang Q, Zhao L, Liang M, Dong Y, Yun W, Qiu F, Meng H*, Guo YJ*. Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine. Ther Drug Monit. 38(3): 343-349, 2016.
[5] Wang Q, Liang M, Dong Y, Yun W, Qiu F, Zhao L*, Guo YJ*. Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. Drug Metab Pharmacokinet. 30(3): 209-213, 2015.
[6] Wang TT, Sun YT, Ma WX, Yang ZC, Yang JF, Liu JR, Fan HB, Yang Y, Gu JK*, Fawcett, JP, Guo YJ*. Trantinterol, a Novel β2 adrenoceptor agonist, noncompetitively inhibits P glycoprotein function in vitro and in vivo. Mol. Pharmaceutics. 12(1): 1-9, 2015.
[7] Zhu X, Yun WT, Sun XF, Qiu F, Zhao LM*, Guo YJ*. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 15(15): 1867-1879, 2014.
[8] Zhu H#, Guo YJ#, Feng XM, Zhang RS, Zhou CK, Li GB, Liu JY*. Familial Cerebral Cavernous Angiomas: Clinical and Genetic Features in a Chinese Family with a Frame-Shift Mutation in the CCM1 Gene (krit1), J Mol Neurosci. 54(4): 790-795, 2014.
[9] Yun W, Zhang F, Hu C, Luo X, Xue P, Wang J, Ge Y, Meng H*, Guo YJ*. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res.107(3): 231-237, 2013 .
[10] Zhang F, Hu C, Dong Y, Lin MS, Liu J, Jiang X, Ge Y, Guo YJ*. The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Arch Biochem Biophys. 535(2): 120-127, 2013 .
[11] Guo YJ, Hu Cheng, He Xiaojing, Qiu Feng, Zhao Limei*. Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy, Drug Metab Pharmacokinet. 27: 536-542, 2012.
[12] Liu JY, Jiang XM, Zhang M, Guo YJ*. Analysis of mitochondrial haplogroups associated with TTR Val30Ala familial amyloidotic polyneuropathy in Chinese patients, Int J Neurosci. 122: 716-718, 2012.
[13] Wang G, He J, Zhao J, Yun W, Xie C, Taub JW,Azmi A,Mohammad RM, Dong Y, Kong W, Guo YJ*, Ge Y*. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer, PLoS One.7(12): e52095, 2012.
[14] Guo YJ, Xu X, Qi W, Xie C, Wang G, Zhang A, Ge Y*.Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines, Mol Med Report. 5(3): 734-738, 2012.
[15] Muharnmad F, Guo MY, Qi WX, Sun FX, Wang AF, Guo YJ*, Zhu GS*. 2pH-triggered controlled drug release from mesoporous silica nanoparticles via intracelluar dissolution of ZnO nanolids, J Am Chem Soc. 133(23): 8778-8781, 2011.
[16] Liu JY, Guo YJ, Zhou CK, Ye YQ, Feng JQ, Yin F, Jiang XM*. Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family, J Neurol Sci. 304(1-2): 83-86, 2011.
[17] Meng HM, Guo GM, Ren JY, Zhou H, Ge YB, Guo YJ*. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy, Epilepsy Behav. 21(1): 27-30, 2011.
[18] Guo YJ, Zhang YF, Wang Y, Chen XY, Si DY, Zhong DF, Fawcett JP, Zhou H*. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metabolism and Disposition. 59:14-17, 2005.
[19] Guo YJ, Wang Y, Si DY, Fawcett JP, Zhong DF, Zhou H*. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 35:853-861, 2005.
*通讯作者
主持和参加的项目：
国家自然科学基金31071105，基于HDACs调控的丙戊酸肝毒性机制及其生物标记物研究，2017/01-2020/12, 54万元，主要参加人
国家自然科学基金 81302857，microRNA 表达水平及相关基因多态性对拉莫三嗪体内代谢影响的研究，2014/01-2016/12，23 万元，主要参加人
国家自然科学基金31071105转甲状腺素蛋白Val30Ala 突变在家族型淀粉样多神经病中的作用机制研究2011年-2013年，34万元，负责人
|
